1. Home
  2. MESO vs PDM Comparison

MESO vs PDM Comparison

Compare MESO & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • PDM
  • Stock Information
  • Founded
  • MESO 2004
  • PDM 1997
  • Country
  • MESO Australia
  • PDM United States
  • Employees
  • MESO N/A
  • PDM N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • PDM Building operators
  • Sector
  • MESO Health Care
  • PDM Real Estate
  • Exchange
  • MESO Nasdaq
  • PDM Nasdaq
  • Market Cap
  • MESO 1.1B
  • PDM 1.3B
  • IPO Year
  • MESO N/A
  • PDM N/A
  • Fundamental
  • Price
  • MESO $10.18
  • PDM $9.50
  • Analyst Decision
  • MESO Strong Buy
  • PDM Strong Buy
  • Analyst Count
  • MESO 4
  • PDM 2
  • Target Price
  • MESO $11.50
  • PDM $11.00
  • AVG Volume (30 Days)
  • MESO 215.6K
  • PDM 945.4K
  • Earning Date
  • MESO 08-28-2024
  • PDM 10-24-2024
  • Dividend Yield
  • MESO N/A
  • PDM 5.27%
  • EPS Growth
  • MESO N/A
  • PDM N/A
  • EPS
  • MESO N/A
  • PDM N/A
  • Revenue
  • MESO $5,902,000.00
  • PDM $572,424,000.00
  • Revenue This Year
  • MESO $66.05
  • PDM N/A
  • Revenue Next Year
  • MESO $348.27
  • PDM N/A
  • P/E Ratio
  • MESO N/A
  • PDM N/A
  • Revenue Growth
  • MESO N/A
  • PDM N/A
  • 52 Week Low
  • MESO $1.61
  • PDM $5.78
  • 52 Week High
  • MESO $12.18
  • PDM $11.12
  • Technical
  • Relative Strength Index (RSI)
  • MESO 54.91
  • PDM 38.40
  • Support Level
  • MESO $10.00
  • PDM $9.19
  • Resistance Level
  • MESO $10.98
  • PDM $10.45
  • Average True Range (ATR)
  • MESO 0.59
  • PDM 0.28
  • MACD
  • MESO 0.06
  • PDM -0.08
  • Stochastic Oscillator
  • MESO 47.92
  • PDM 20.26

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About PDM Piedmont Office Realty Trust Inc.

Piedmont Office Realty Trust Inc is a real estate investment trust engaged in the acquisition, development, and management of commercial real estate properties throughout the U.S. The company's real estate portfolio is mainly composed of office properties located in the majority of American metropolitan areas. Piedmont derives majority of its revenue in the form of rental income from tenants in mid- to long-term lease agreements. The vast majority of the company's revenue comes from the leasing of its assets in Washington D.C., New York City, Chicago, Atlanta, Minneapolis, Dallas, and Boston. Piedmont's large customers in terms of rental revenue are U.S. Government entities, business services companies, and financial institutions.

Share on Social Networks: